<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the 🔗 symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updpates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://ord.cloudcm.om/0&EID=38044](https://stanford.cltrdcoud-cme.com/default.aspx?P=0&EID=3804ulsp4).
   Please include readable ctent in the bracket, e.gi.[io](https://tanor.locecodefault.s?=03804).

7. PlatsP30)

 ease do not delete this instructi
### Ce lnicaTrials (Nov ](/page/updapbr](pgdttes/#clinical.trials)
[16 clinica trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planne linical Tials of ntiviral Compounds.](/clinical-trials/?fromDrate=2020-11-12)

### Database Entries (Nov 13)
Cornelissen L, Hoefsmit E, et int., and Blank CU. [“Nafamostat Mesylate in lipid carrier for nasal SARS-CoV2tiias eduction in a hamster model.”](/search/?article=Cornelissen20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.09.372375](https://doi.org/10.1101/2020.11.09.372375).
### Database Entries (Nov 13)
Feld JJ, Kandel C, et int., ang.(d Hansen B. [“Peginterferon-lambda for the treatment of COVID-19 in outpatients.”](/search/?article=Feld20) _medRxiv_, 2020. [doi.org/10.1101/2020.11.09.20228098](https://doi.org/10.1101/2020.11.09.20228098).
### Database Entries (Nov 13)
Lee S, Kim C, et int., and Choi YK. [“A Novel NeutralizingA Antibody Targeting Receptor Binding Domain of SARS-CoV-2.”](/search/?article=Lee20b) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-59639/v1](https://doi.org/10.21203/rs.3.rs--0)

### [Pubbed preprints - w eek of November 9](/geudts/prebprints.peer-reviewed.publications)
[Beddingfield BJ](/search/?article=Beddingfield20) (_JACC Basic Transl Sci_); [Chen CZ](/search/?article=Chen20f) (_ACS Pharmacol. Transl. Sci._); [Ghahremanpour MM](/search/?article=Ghahremanpour20) (_ACS Med. Chem. Lett._); [Lou Y](/search/?article=Lou20) (_EJPS_); [Tandon R](/search/?article=Tandon20) (_Journal of Virology_);
### Database Entries (Nov 09)
Westberg M, Su Y, et int., and Lin MZ. [“Rational design of a new class of protease inhiitorsfor ential treatment of coronavirus diseases.”](/search/?article=Westberg20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.15.275891](https://doi.org/10.1101/2020.09.15.275891).
### Database Entries (Nov 07)
Chi X, Liu X, et int., and Yang W. [“Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.”](/search/?article=Chi20b) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-18387-8](https://doi.org/10.1038/s41467-020-18387-8). \[[PubMed32913273](https://www.ncbi.nlm.nih.gov/pubmed/32913273/)\] \[[PMC7483421](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483421/)\]
### Database Entries (Nov 07)
de Vries RD, Schmitz KS, et int., and Porotto M. [“Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets.”](/search/?article=deVries20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.04.361154](https://doi.org/10.1101/2020.11.04.361154).

### [Published preprints - week of November 2](/page/updates/#preprints.peer-reviewed.publications)
[Custódio TF](/search/?article=Custodio20) (_Ncomms_); [Schoof M](/search/?article=Schoof20) (_Science_); [Li W](/search/?article=Li20b) (_PNAS_); [Kreye J](/search/?article=Kreye20) (_Cell_); [Matsuyama S](/search/?article=Matsuyama20) (_JVI_);
### [Clinical Trials (Nov 05)](/page/upgdates/#clinical.trials)
[4 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-11-05)

### Database Entries (Nov 05)
Bojkova D, Bechtel M, et int., and Cinatl J. [“Aprotinin Inhibits SARS-CoV-2 Replication.”](/search/?article=Bojkova20c) _Cells_, 2020. [doi.org/10.3390/cells9112377](https://doi.org/10.3390/cells9112377). \[[PubMed33143316](https://www.ncbi.nlm.nih.gov/pubmed/33143316/)\]
### Database Entries (Nov 05)
Li Y, Cao L, et int., and Zhang X. [“Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mice Models.”](/search/?article=Li20g) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.353300](https://doi.org/10.1101/2020.10.26.353300).
### Database Entries (Nov 04)
Cai Y, Xu W, et int., and Jiang S. [“Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit.”](/search/?article=Cai20b) _Virologica Sinica_, 2020. [doi.org/10.1007/s12250-020-00305-3](https://doi.org/10.1007/s12250-020-00305-3). \[[PubMed33052520](https://www.ncbi.nlm.nih.gov/pubmed/33052520/)\] \[[PMC7554295](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554295/)\]
### Database Entries (Nov 04)
Weisblum Y, Schmidt F, et int., and Bieniasz PD. [“Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.”](/search/?article=Weisblum20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.21.214759](https://doi.org/10.1101/2020.07.21.214759). \[[PubMed32743579](https://www.ncbi.nlm.nih.gov/pubmed/32743579/)\] \[[PMC7386497](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386497/)\]
### Database Entries (Nov 04)
Yuan S, Yin X,iv doior.102020.t of en, Dis  et int., and Yuen K. [“Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters.”](/search/?article=Yuan20e) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-86169/v1](https://doi.org/10.21203/rs.3.rs-86169/v1). \[[PubMed33052331](https://www.ncbi.nlm.nih.gov/pubmed/33052331/)\] \[[PMC7553155](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553155/)\]
### [Preprints => Peer-Reviewed Publications (Nov 4)](/page/updates/#uprepreints.peer-reviewed.publications)
1 published preprints were added.
### Database Entries (Nov 03)
Bakovic A, Risner K, et int., and Narayanan A. [“Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2.”](/search/?article=Bakovic20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.29.352450](https://doi.org/10.1101/2020.10.29.352450).
### Database Entries (Nov 03)
Chan CE, Seah SG, et int., and Hanson BJ. [“The Fc-mediated effector functions of a potent SARS-Cn sw-ooV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.”](/search/?article=Chan20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.355107](https://doi.org/10.1101/2020.10.26.355107).
### Database Entries (Nov 03)
Fu Y, Maruyama J, et int., and Allen RD. [“Protective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model.”](/search/?article=Fu20c) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.28.359836](https://doi.org/10.1101/2020.10.28.359836).
### Database Entries (Nov 03)
Halfon P, Bestion E, et int., and Schinazi RF. [“GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition.”](/search/?article=Halfon20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.06.327635](https://doi.org/10.1101/2020.10.06.327635). \[[PubMed33052342](https://www.ncbi.nlm.nih.gov/pubmed/33052342/)\] \[[PMC7553169](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553169/)\]
### Database Entries (Nov 03)
Hashim HA, Maulood MF, et int., and Abdulamir AS. [“Controlled randomized c linical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq.”](/search/?article=Hashim20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.26.20219345](https://doi.org/10.1101/2020.10.26.20219345).
### Database Entries (Nov 03)
Li T, Sun L, et int., and Shen X. [“Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study.”](/search/?article=Li20f) _Clinical and Translational Science_, 2020. [doi.org/10.1111/cts.12881](https://doi.org/10.1111/cts.12881). \[[PubMed32881359](https://www.ncbi.nlm.nih.gov/pubmed/32881359/)\]
### Database Entries (Nov 03)
Mellott D, Tseng C, et int., and McKerrow JH. [“A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells.”](/search/?article=Mellott20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.23.347534](https://doi.org/10.1101/2020.10.23.347534).
### Database Entries (Nov 03)
Rosenfeld R, Noy-Porat T, et int., and Mazor O. [“Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody.”](/search/?article=Rosenfeld20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.26.354811](https://doi.org/10.1101/2020.10.26.354811).
### Database Entries (Nov 03)
Zandi K, Amblard F, et int., and Schinazi RF. [“Repurposing Nucleoside Analogs for Human Coronaviruses.”](/search/?article=Zandi20) _Antimicrobial Agents and Chemotherapy_, 2020. [doi.org/10.1128/aac.01652-20](https://doi.org/10.1128/aac.01652-20). \[[PubMed33122172](https://www.ncbi.nlm.nih.gov/pubmed/33122172/)\]

### [Preprints => Peer-Reviewed Publications (Nov 3)](/page/updates/#preue.prints.peer-reviewed.publications)

2 published preprints were added.

### Database Entries (Nov 02)
Cao X, Maruyama J, et int., and Allen RD. [“Discovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach.”](/search/?article=Cao20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.27.316174](https://doi.org/10.1101/2020.09.27.316174).

### [Press Release (Oct 30)](/page/updates/#press.release)
[Regn-cov2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201030.pdf)

### [Clinical Trials (Oct 29)](/page/updates/#clinical.trials)
[11 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-29)

### Database Entries (Oct 29)
Chen P, Nirula A, et int., and Skovronsky DM. [“SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.”](/search/?article=Chen20l) _New England Journal of Medicine_, 2020. [doi.org/10.1056/nejmoa2029849](https://doi.org/10.1056/nejmoa2029849). \[[PubMed33113295](https://www.ncbi.nlm.nih.gov/pubmed/33113295/)\]
### [Press Release (Oct 28)](/page/updates/#press.release)
[Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN- COV2 Antibody Cocktail Signifi cantly Reduced Virus Levels and Need for Further Medical Attention](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Regeneron20201028.pdf)

### [Press Release (Oct 26)](/page/updates/#press.release)

[Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Lilly20201027.pdf)

### Database Entries (Oct 26)
Pan H, Peto R, et int., and Swaminathan S. [“Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results.”](/search/?article=Pan20b) _medRxiv_, 2020. [doi.org/10.1101/2020.10.15.20209817](https://doi.org/10.1101/2020.10.15.20209817).
### Database Entries (Oct 26)
Rocco PRM, Silva PL, et int., and Lapa e Silva JR. [“Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial.”](/search/?article=Rocco20) _medRxiv_, 2020. [doi.org/10.1101/2020.10.21.20217208](https://doi.org/10.1101/2020.10.21.20217208).

### [Clinical Trials (Oct 22)](/page/updates/#clinical.trials)
[16 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-22)
### Database Entries (Oct 22)
Rosenke K, Leventhal S, et int., and Stein DA. [“Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino-oligomers.”](/search/?article=Rosenke20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.29.319731](https://doi.org/10.1101/2020.09.29.319731). \[[PubMed33024974](https://www.ncbi.nlm.nih.gov/pubmed/33024974/)\] \[[PMC7536879](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536879/)\]
### Database Entries (Oct 22)
Yin W, Luan X, et int., and Xu HE. [“Structural basis for repurposing a 100-years-old drug suramin for treating COVID-19.”](/search/?article=yin20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.06.328336](https://doi.org/10.1101/2020.10.06.328336).

### [Press Release (Oct 16)](/page/updates/#press.release)
- [IFN Lambda EigerBioPharmaceuticals](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-prod/downloads/press-release/Eiger20201017.pdf)

### [Clinical Trials (Oct 15)](/page/updates/#clinical.trials)
[5 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-15)
e.g. vieord.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->

### Database Entries (Oct 13)
Olaleye OA, Kaur M, and Onyenaka CC. [“Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein’s Receptor Binding Domain and Recombinant Human ACE2.”](/search/?article=Olaleye20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.13.295691](https://doi.org/10.1101/2020.09.13.295691). \[[PubMed32995775](https://www.ncbi.nlm.nih.gov/pubmed/32995775/)\] \[[PMC7523101](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523101/)\]

### Database Entries (Oct 13)
Kaptein SJF, Jacobs S, et int., and Delang L. [“Favipiravir at high doses has potent antiviral activity in  etint. an aer  e noodesn o comoa SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity.”](/search/?article=Kaptein20) _Proceedings of the National Academy of Sciences_, 2020. [doi.org/10.1073/pnas.2014441117](https://doi.org/10.1073/pnas.2014441117). \[[PubMed33037151](https://www.ncbi.nlm.nih.gov/pubmed/33037151/)\]

### Database Entries (Oct 12)
Arabi YM, Asiri AY, et int., and Alothman A. [“Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome.”](/search/?article=Arabi20) _NEJM_, 2020. [doi.org/10.1056/nejmoa2015294](https://doi.org/10.1056/nejmoa2015294). \[[PubMed33026741](https://www.ncbi.nlm.nih.gov/pubmed/33026741/)\]
### Database Entries (Oct 12)
Beigel JH, Tomashek KM, et int., and Lane HC. [“Remdesivir for the Treatment of Covid-19 — Final Report.”](/search/?article=Beigel20) _NEJM_, 2020. [doi.org/10.1056/nejmoa2007764](https://doi.org/10.1056/nejmoa2007764). \[[PubMed32445440](https://www.ncbi.nlm.nih.gov/pubmed/32445440/)\] \[[PMC7262788](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/)\]
### Database Entries (Oct 12)
Cho J, Lee YJ, et int., and Choi J. [“Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.”](/search/?article=Cho20) _SREP_, 2020. [doi.org/10.1038/s41598-020-72879-7](https://doi.org/10.1038/s41598-020-72879-7). \[[PubMed33004837](https://www.ncbi.nlm.nih.gov/pubmed/33004837/)\] \[[PMC7530981](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530981/)\]
### Database Entries (Oct 12)
Gilmore K, Zhou Y, et int., and Seeberger PH. [“In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2[Newly added referencetes/#changelog)

Brunaugh AD, Seo H, et int., and Smyth HD. [“Broad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.”](/search/?article=GilmoreBrunaugh20) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.05.32663709.24.310490](https://doi.org/10.1101/2020.10.05.326637).09.24.310490).

### [Preprints => Peer-Reviewed Publications (Oct lading ceestas.

### [oa 12)](/page/updates/#preprints.peer-reviewed.publications)

3 publishNewly added preprints were added.

### [Clinical Trials (Oct 09)](/page/updates/#clinical.trials)
[23 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-08)


### [New spike structures (Oct 08)](/page/spike-structures/#fig11ure.11.phylogenetic.tree.multiple.sequence.alignment.and.sequence.variability.of.the.sars-related.coronavirus.sarsr-cov.spike.receptor.binding.domain.rbd.)
Figure 11. Phylogenetic tree, multiple sequence alignment, and sequence variability of the SARS-related coronavirus (SARSr-CoV) spike receptor binding domain (RBD).

### [New spike structures (Oct 08)](/page/spike-structures/#fig12ure.12.phylogenetic.tree.multiple.sequence.alignment.and.sequence.variability.of.the.sars-related.coronavirus.sarsr-cov.trimeric.spike.)
Figure 12. Phylogenetic tree, multiple sequence alignment, and sequence variability of the SARS-related coronavirus (SARSr-CoV) trimeric spike.

### Webinar (Oct 07)
Monoclonal Antibodies for the Prevention and Treatment of COVID 19. [video](https://www.youtube.com/watch?v=YUj9jBlTCrY)

### [Press Release (Oct 07)](/page/updates/#press.-release)
- [Lilly SARS-CoV-2 Neutralizing Antibody Slides Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-proddev/downloads/press-release/Lilly202010071.pdf)
- [Lilly update on SARS-CoV-2 neutralizing antibody programs Oct7](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-proddev/downloads/press-release/Lilly202010072.pdf)

### Database Eentries (Oct 05)
Ansarin K, Tolouian R, et int., and Chapman KR. [“Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.”](/search/?article=Ansarin20) _BioImpacts_, 2020. [doi.org/10.34172/bi.2020.27](https://doi.org/10.34172/bi.2020.27). \[[PubMed32983936](https://www.ncbi.nlm.nih.gov/pubmed/32983936/)\] \[[PMC7502909]\](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502909/)
### Database Eentries (Oct 05)
Wahl A, Gralinski L, et int., and Garcia JV. [“Acute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801.”](/search/?article=Wahl20) _Research square_, [2020. doi.org/10.21203/rs.3.rs-80404/v1](https://doi.org/10.21203/rs.3.rs-80404/v1). \[[PubMed32995766](https://www.ncbi.nlm.nih.gov/pubmed/32995766/)\] \[[PMC7523135](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523135/)\]
### Database Eentries (Oct 03)
Jones BE, Brown-Augsburger PL, et int., and Falconer E. [“LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.”](/search/?article=Jones20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.30.318972](https://doi.org/10.1101/2020.09.30.318972).
### Database Eentries (Oct 03)
Sagar S, Rathinavel AK, et int., and Radhakrishnan P. [“Bromelain Iference (Sep 29)](/page/updates/#changelog)

Curreli F, Victor SMB, et int., and Debnath AK. [“Stapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibits SARS-CoV-2 Iinfection in VeroE6 Cellsvitro.”](/search/?article=SagarCurreli20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.16.297366](https://doi.org/10.1101/2020.09.16.297366). \[[PubMed32995771](https://www.ncbi.nlm.nih.gov/pubmed/32995771/)\] \[[PMC7523097](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523097/)\]
### Database Eentries (Oct 03)
Watson A, Ferreira L, et int., and Stroud R. [“Peptide Antidotes to SARS-CoV-2 (COVID-19).”](/search/?article=Watson20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.06.238915](https://doi.org/10.1101/2020.08.06.238915).

### [Press Release (Oct 02)](/page/updates/#press.-release)

[Synairgen plc, Interim results for the six months ended 30 June 2020](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-proddev/downloads/press-release/Synairgen20200930.pdf)

### [Press Release (Oct 02)](/page/updates/#press.-release)

[Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19outpatient setting](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-proddev/downloads/press-release/Lilly20200930.pdf)

### [Press Release (Oct 02)](/page/updates/#press.-release)

[Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms inNon-Hospitalized COVID-19 Patients](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-proddev/downloads/press-release/Regeneron20200930.pdf)

### [Clinical Trials (Oct 01)](/page/updates/#clinical.trials)
[9 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the reg8.25.266437](https://doi.org/10.1101/2020.08.25.266437).

### [New clinical trials (Sep 28)](/page/updates/#new.clinical.trials.sep.28.)

14 clinical trials were added since September 24: [listry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-10-01)

### Database entries (Oct 01)
Proud PC, Tsitoura D, et int., and Carroll MW. [“Prophylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.”](/search/?article=Proud20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.309914](https://doi.org/10.1101/2020.09.25.309914).
### Database entries (Oct 01)
Son J, Huang S, et int., and Ding S. [“Nitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model.”](/search/?article=Son20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.312165](https://doi.org/10.1101/2020.09.24.312165).
### Database entries (Oct 01)
Fagre AC, Manhard J, et int., and Schountz T. [“A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.”](/search/?article=Fagre20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.313601](https://doi.org/10.1101/2020.09.25.313601).
### Database entries (Oct 01)
Lin C, Li Y, et int., and Chen J. [“Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction.”](/search/?article=Lin20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.14.295956](https://doi.org/10.1101/2020.09.14.295956).
### Database entries (Oct 01)
Xiao T, Lu J, et int., and Chen B. [“A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.”](/search/?article=Xiao20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.18.301952](https://doi.org/10.1101/2020.09.18.301952). \[[PubMed32995768](https://www.ncbi.nlm.nih.gov/pubmed/32995768/)\] \[[PMC7523094](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523094/)\]
### Database entries (Oct 01)
Zhang L, Cao L, et int., and Zhu F. [“A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.”](/search/?article=Zhang20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.23.309294](https://doi.org/10.1101/2020.09.23.309294).
### Database entries (Sep 29)
Brunaugh AD, Seo H, et int., and Smyth HD. [“Broad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.”](/search/?article=Brunaugh20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.310490](https://doi.org/10.1101/2020.09.24.310490).
### Database entries (Sep 29)
Curreli F, Victor SMB, et int., and Debnath AK. [“Stapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro.”](/search/?article=Curreli20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.25.266437](https://doi.org/10.1101/2020.08.25.266437).
### Database entries (Sep 25)
new clinical trials](/clinical-trials/?fromDate=2020-09-24).

### [Published preprints (Sep 28)](/page/updates/#published.preprints.sep.16.sep.28.)

3 published preprints were added since September 16.

### [Newly added reference (Sep 25)](/page/updates/#changelog)

ter Ellen ter BM, Dinesh Kumar N, et int., and Smit JM. [“Resveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro.”](/search/?article=Ellen%20ter20)  _bioRxiv_,  2020.  [doi.org/10.1101/2020.09.24.285940](https://doi.org/10.1101/2020.09.24.285940).

### Database entries (Sep 24)
Pereda R, González D, et int., and Domínguez RE. [“Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.”](/search/?article=Pereda20) _Journal of Interferon & Cytokine Research_, 2020. [doi.org/10.1089/jir.2020.0124](https://doi.org/10.1089/jir.2020.0124). \[[PubMed32960147](https://www.ncbi.nlm.nih.gov/pubmed/32960147/)\]

### [Clinical Trials (Sep 24)](/page/updates/#clinical.trials)
[10 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-09-04)

### [New [New spike structure (Sep 24)](/page/updates/#new.spike .structure (S.sep .24)](/page/updates/#features.)
We added a figure [Naturally occurring spike RBD variants and mAb escape mutations](/page/spike-structures/#fig10).

### [New table added (Sep 24)](/page/updates/#featuresnew.table.added.sep.24.)
We added a [table of mutation annotations for SARS-CoV-2 Spike gene](/page/mutannot-spike-table/) and data for six monoclonal antibodies.

### Database entries (Sep 23)[Newly added reference (Sep 23)](/page/updates/#changelog)

Cao L, Goreshnik I, et int., and Baker D. [“De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.”](/search/?article=Cao20e)  _Science_,  2020.  [doi.org/10.1126/science.abd9909](https://doi.org/10.1126/science.abd9909). \[ [PubMed32907861](https://www.ncbi.nlm.nih.gov/pubmed/32907861/)\]

### [Interface update (Sep 22)](/page/updates/#featuresinterface.update.sep.22.)
We now support downloading CSV/Excel files for tables.

### [Editorial (Sep 21)](/page/updates/#papers)

Shafer R. “A SARS-CoVa.sars-cov-2 .antiviral .therapy score card” _Global Health & Medicine_, 2020. [doi.org/10.35772/ghm.2020.01082](https://doi.org/10.35772/ghm.2020.01082).

### [Preprints => Peer-Reviewed Publications (Sep 16)](/page/updates/#preprints.peer-reviewed.publications)

3 published preprints were added.

### Database entries (Sep 15)
Li T, Han X, et int., and Jin A. [“A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD.”](/search/?article=Li20e) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.11.292631](https://doi.org/10.1101/2020.09.11.292631).
### Database entries (Sep 14)
Cohen-Dvashi H, Weinstein J, et int., and Diskin R. [“Coronacept – a potent immunoadhesin against SARS-CoV-2.”](/search/?article=Cohen-Dvashi20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.12.247940](https://doi.org/10.1101/2020.08.12.247940).
### Database entries (Sep 14)
Glasgow A, Glasgow J, et int., and Wells JA. [“Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.”](/search/?article=Glasgow20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.31.231746](https://doi.org/10.1101/2020.07.31.231746). \[[PubMed32766586](https://www.ncbi.nlm.nih.gov/pubmed/32766586/)\] \[[PMC7402043](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402043/)\]
### Database entries (Sep 14)
Hassan AO, Case JB, et int., and Diamond MS. [“A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.”](/search/?article=Hassan20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.06.011](https://doi.org/10.1016/j.cell.2020.06.011). \[[PubMed32553273](https://www.ncbi.nlm.nih.gov/pubmed/32553273/)\] \[[PMC7284254](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284254/)\]
### Database entries (Sep 14)
Olaleye OA, Kaur M, et int., and Adebusuyi T. [“Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro.”](/search/?article=Olaleye20) _bioRxiv.score.card.sep.21.)

Shafer R. “A SARS-CoV-2 antiviral therapy score card” _Global Health & Medicine_,  2020.  [doi.org/10.1101/2020.08.14.250480](https://doi.org/10.1101/2020.08.14.250480). \[[PubMed32817951](https://www.ncbi.nlm.nih.gov/pubmed/32817951/)\] \[[PMC7430586](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430586/)\]
### Database entries (Sep 14)
de Vries M, Mohamed AS, et int., and Dittmann M. [“Comparative study of a 3CLpro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models.”](/search/?article=Vries20) _bioRxiv_, 2020. [doi.org/10.1101/2020.08.28.272880](https://doi.org/10.1101/2020.08.28.272880). \[[PubMed32869028](https://www.ncbi.nlm.nih.gov/pubmed/32869028/)\] \[[PMC7457613](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457613/)\]
### Database entries (Sep 14)
Zhang Q, Chen CZ, et int., and Ye Y. [“Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro.”](/search/?article=Zhang20e) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.14.202549](https://doi.org/10.1101/2020.07.14.202549). \[[PubMed32699847](https://www.ncbi.nlm.nih.gov/pubmed/32699847/)\] \[[PMC7373127](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373127/)\]35772/ghm.2020.01082](https://doi.org/10.35772/ghm.2020.01082).

<!--stackedit_data:
eyJoaXN0b3J5IjpbLTE4MTkwNDY1MTBdfQ==
-->